Monday, January 13, 2020 Daily Archives

Yposkesi to make Genethon and Sarepta’s DMD gene therapy

Genethon and Sarepta have contracted Yposkesi to make AAV material for a Duchenne muscular dystrophy (DMD) gene therapy they are developing. The therapy in question is called GNT0004. It consists of an AAV-type viral vector and a shortened version of the dystrophin gene (microdystrophin). According to preclinical data published in the journal Nature the therapy is able to produce significant restoration of muscle function with stabilization of clinical symptoms. Under the new manufacturing deal Yposkesi will produce clinical and large-scale…

Tessa and CellVec both set up Singapore plants to support cell & gene therapies

Tessa Therapeutics will open a plant in Singapore for its CAR-T programs, while CellVec has opened a viral vector facility on the island state to support customers’ gene therapy projects. Singapore-based biotech Tessa is developing its own autologous cellular therapies and has told us it plans to open a 90,000 square-foot plant to support clinical and commercial efforts. “Tessa will use the new facility for the clinical and future commercial manufacturing of our late-stage clinical programs,” the firm said, adding…

UMass Lowell opens pilot freeze-drying development lab

UMass Lowell has opened a lyophilization testing facility where researchers and biopharma can develop freeze-drying processes in a non GMP environment. The facility – dubbed LyoBay – is located in the Mark and Elisia Saab Emerging Technologies and Innovation Center at UMass Lowell, which is located northwest of Boston. It is intended as a development space for scientists and biopharmaceutical companies according to executive director, Karen Hamlin. “The LyoBay offers users the opportunity to take their product technology from the…